1. Search Result
Search Result
Results for "

growth,factor

" in MedChemExpress (MCE) Product Catalog:

345

Inhibitors & Agonists

11

Screening Libraries

2

Fluorescent Dye

2

Biochemical Assay Reagents

50

Peptides

2

MCE Kits

25

Inhibitory Antibodies

43

Natural
Products

517

Recombinant Proteins

10

Isotope-Labeled Compounds

54

Antibodies

6

Click Chemistry

15

Oligonucleotides

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-P3601

    FGF basic (1-24)

    Bacterial HBV Infection Inflammation/Immunology
    Brain Derived Basic Fibroblast Growth Factor (1-24) (FGF basic 1-24) is a synthetic peptide, shows anti-bacterial and anti-HBV activities. Brain Derived Basic Fibroblast Growth Factor (1-24) can be used in infection disease and immune disease research .
    Brain Derived Basic Fibroblast Growth Factor (1-24)
  • HY-P1777

    Insulin-like Growth Factor I (24-41)

    IGF-1R Metabolic Disease Inflammation/Immunology
    IGF-I (24-41) (Insulin-like Growth Factor I (24-41)) is amino acids 24 to 41 fragment of IGF-I. IGF-I, a 70 aa polypeptide hormone, is a trophic factor for both neurons and glial cells. IGF-I is partly responsible for systemic growth hormone (GH) activities. IGF-I has anabolic, antioxidant, anti-inflammatory and cytoprotective actions. IGF-I (24-41) regulates somatic growth and behavioral development .
    IGF-I (24-41)
  • HY-U00002

    VEGFR EGFR Cancer
    ZD-4190 is a potent, orally available inhibitor of the vascular endothelial cell growth factor receptor 2 (VEGFR2) and of epidermal growth factor receptor (EGFR) signalling, used for the treatment of cancer.
    ZD-4190
  • HY-147243

    ANG-3070

    VEGFR PDGFR Cardiovascular Disease Inflammation/Immunology
    Ansornitinib is an orally active dual kinase inhibitor that inhibits platelet-derived growth factor receptor (PDGFR) and vascular endothelial growth factor receptor (VEGFR2). Ansornitinib can be used as an antifibrotic agent in lung, liver, kidney, and gastrointestinal fibrotic diseases .
    Ansornitinib
  • HY-B1016

    AR-12008

    PDGFR Cardiovascular Disease Cancer
    Trapidil is a vasodilator, an antiplatelet active molecule with specificity for platelet-derived growth factor.
    Trapidil
  • HY-17622
    Tavilermide
    2 Publications Verification

    MIM-D3

    Trk Receptor Inflammation/Immunology
    Tavilermide is a selective, partial agonist of TrkA, or a nerve growth factor (NGF) mimetic.
    Tavilermide
  • HY-P1085

    EGFR Cancer
    Epidermal Growth Factor Receptor Peptide (985-996) is an amino acid peptide fragment derived from positions 985-996 in epidermal growth factor receptor (EGFR) .
    Epidermal Growth Factor Receptor Peptide (985-996)
  • HY-P1773A

    Insulin-like Growth Factor I (30-41) (TFA)

    IGF-1R Metabolic Disease Inflammation/Immunology
    IGF-I (30-41) (TFA) is amino acids 30 to 41 fragment of Insulin-like Growth Factor I (IGF-I). IGF-I is partly responsible for systemic GH activities although it possesses a wide number of own properties (anabolic, antioxidant, anti-inflammatory and cytoprotective actions) .
    IGF-I (30-41) (TFA)
  • HY-P1777A

    Insulin-like Growth Factor I (24-41) (TFA)

    IGF-1R Metabolic Disease Inflammation/Immunology
    IGF-I (24-41) (Insulin-like Growth Factor I (24-41)) TFA is amino acids 24 to 41 fragment of IGF-I. IGF-I TFA, a 70 aa polypeptide hormone, is a trophic factor for both neurons and glial cells. IGF-I TFA is partly responsible for systemic growth hormone (GH) activities. IGF-I TFA has anabolic, antioxidant, anti-inflammatory and cytoprotective actions. IGF-I (24-41) TFA regulates somatic growth and behavioral development .
    IGF-I (24-41) (TFA)
  • HY-123392

    PDGFR Cardiovascular Disease
    Sch 13835 is a platelet-derived growth factor (PDGFR) inhibitor .
    Sch 13835
  • HY-159840

    FGFR Cancer
    Fanregratinib is a fibroblast growth factor receptor (FGFR) tyrosine kinase inhibitor .
    Fanregratinib
  • HY-153484A

    VEGFR Small Interfering RNA (siRNA) Others
    Bevasiranib sodium is a siRNA designed to silence the genes that produce vascular endothelial growth factor (VEGF). It is widely accepted that vascular endothelial growth factor (VEGF) is a key component in the pathogenesis of choroidal neo-vascularization (CNV), which is a precursor to wet age-related macular degeneration (wet AMD).
    Bevasiranib sodium
  • HY-153484

    VEGFR Small Interfering RNA (siRNA) Others
    Bevasiranib is a siRNA designed to silence the genes that produce vascular endothelial growth factor (VEGF). It is widely accepted that vascular endothelial growth factor (VEGF) is a key component in the pathogenesis of choroidal neo-vascularization (CNV), which is a precursor to wet age-related macular degeneration (wet AMD).
    Bevasiranib
  • HY-101493
    SUN11602
    1 Publications Verification

    FGFR Neurological Disease
    SUN11602 is a novel aniline compound with basic fibroblast growth factor-like activity.
    SUN11602
  • HY-W001179
    2,5-Dihydroxybenzoic acid
    2 Publications Verification

    Endogenous Metabolite FGFR Others
    2,5-Dihydroxybenzoic acid is a derivative of benzoic and a powerful inhibitor of fibroblast growth factors.
    2,5-Dihydroxybenzoic acid
  • HY-159503

    3D185 free base; HH185 free base

    Others Cancer
    Segigratinib is a fibroblast growth factor receptor tyrosine kinase inhibitor, with antineoplastic effect .
    Segigratinib
  • HY-114667

    EGFR Others
    Lavendustin C6 is a specific inhibitor of tyrosine kinase. Lavendustin C6 inhibits epidermal growth factor (EGF) receptor tyrosine kinase with an EC50 value of 0.05 μg/mL. Lavendustin C6 inhibits platelet-derived growth factor (PDGF)-induced inositol phosphate formation .
    Lavendustin C6
  • HY-118203

    FGFR PDGFR Insulin Receptor Cancer
    SU4984 is a protein tyrosine kinase inhibitor, with an IC50 of 10-20 μM for fibroblast growth factor receptor 1 (FGFR1). SU4984 is also inhibits platelet-derived growth factor receptor, and insulin receptor. SU4984 can be used for the research of cancer .
    SU4984
  • HY-P99823

    TA-46; sFGFR3

    FGFR Others
    Recifercept (TA-46) is a soluble, recombinant fibroblast growth factor receptor 3 (FGFR3) molecule. Recifercept can be used as a decoy/ligand trap to decrease the amount of fibroblast growth factors that can bind to mutant FGFR3 receptors. Recifercept can be used for the research of achondroplasia .
    Recifercept
  • HY-164718

    EGFR Cancer
    Sevabertinib is an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor with antitumor activity .
    Sevabertinib
  • HY-136209

    VEGFR Cancer
    SU5208 inhibits vascular endothelial growth factor receptor-2 (VEGFR2) .
    SU5208
  • HY-N11004

    Others Neurological Disease
    Erinacine C is a potent stimulator. Erinacine C can be used for nerve-growth factor synthesis .
    Erinacine C
  • HY-117224

    Formylpteroic acid

    Endogenous Metabolite Endocrinology
    Rhizopterin is a growth factor that can form rhizobactin de novo in synthetic medium lacking folate .
    Rhizopterin
  • HY-112720
    AGL-2263
    1 Publications Verification

    Insulin Receptor Metabolic Disease Endocrinology
    AGL-2263 is an insulin receptor and insulin-like growth factor (IGF) receptor inhibitor .
    AGL-2263
  • HY-B0025

    Glycosidase Metabolic Disease
    Voglibose is an orally active alpha-glucosidase inhibitor that prevents the development of colorectal precancerous lesions induced by obesity and diabetes. Voglibose reduces oxidative stress in an inflammatory environment and inhibits the insulin-like growth factor/insulin-like growth factor-1 receptor (IGF/IGF-1R) functional axis .
    Voglibose
  • HY-149462

    PDGFR Cardiovascular Disease
    KN1022 an inhibitor of phosphorylation of platelet-derived growth factor receptor (PDGFR) with IC50 of 0.24 μM .
    KN1022
  • HY-160048

    PDGFR Cancer
    PEG40K unconjugated/naked AX102 sodium is AX102 without PEG40K conjugation. AX102 is a DNA oligonucleotide aptamer for platelet-derived growth factor PDGF-B. AX102 is 34 bases in length, selectively binds platelet-derived growth factor B (PDGF-B), and causes tumor vessel regression .
    PEG40K unconjugated/naked AX102 sodium
  • HY-137455

    ANG-3777

    c-Met/HGFR Inflammation/Immunology
    Terevalefim (ANG-3777), an hepatocyte growth factor (HGF) mimetic, selectively activates the c-Met receptor .
    Terevalefim
  • HY-108627

    PDGFR Others
    DMPQ dihydrochloride is a potent and selective inhibitor of human platelet-derived growth factor receptor β (PDGFRβ) with an IC50 of 80 nM .
    DMPQ dihydrochloride
  • HY-P99200

    Trk Receptor Neurological Disease
    Fulranumab is a human IgG2 monoclonal antibody against nerve growth factor (NGF) and can be used for the research of pain .
    Fulranumab
  • HY-12043
    SB 525334
    10+ Cited Publications

    TGF-β Receptor Cancer
    SB 525334 is a potent and selective transforming growth factor β1 receptor (ALK5) inhibitor with an IC50 of 14.3 nM.
    SB 525334
  • HY-142967

    TGF-β Receptor Cancer
    TGFβ-IN-1 is an antitumor growth and metastasis agent through inhibiting the transforming growth factor‑β signaling pathway.
    TGFβ-IN-1
  • HY-157420

    VEGFR Cardiovascular Disease
    VEGFR-2-IN-38 (compound 3) is a potential vascular endothelial growth factor receptor-2 inhibitor .
    VEGFR-2-IN-38
  • HY-13783

    TGF-β Receptor Cancer
    BIBF0775 is a potent and selective transforming growth factor β (TGFβ) type I receptor (Alk5) inhibitor with an IC50 of 34 nM.
    BIBF0775
  • HY-11055

    Others Neurological Disease
    KP 544 is a potent neurotrophic protein enhancer that amplifies nerve growth factor (NGF)-induced neurite outgrowth of PC12 cells and SH-SY5Y neuroblastoma cells. KP544 also enhances choline acetyltransferase activity. KP 544 selectively interact in the differentiation pathway downstream of MAPK in a manner that amplifies nerve growth factor and cyclic AMP effects and is also neuroprotective .
    KP 544
  • HY-15494
    Picropodophyllin
    15+ Cited Publications

    AXL1717; Picropodophyllotoxin; PPP

    IGF-1R Apoptosis Endocrinology Cancer
    Picropodophyllin (AXL1717) is a selective insulin-like growth factor-1 receptor (IGF-1R) inhibitor with an IC50 of 1 nM.
    Picropodophyllin
  • HY-17601
    Alofanib
    3 Publications Verification

    RPT835

    FGFR Apoptosis Cardiovascular Disease Cancer
    Alofanib (RPT835) is a potent and selective allosteric inhibitor of fibroblast growth factor receptor 2 (FGFR2). Anticancer and antiangiogenic activity .
    Alofanib
  • HY-N10577

    TGF-beta/Smad Cancer
    Chlorfortunone A is a novel sesquiterpenoid dimers, can be isolated from the roots of Chloranthus fortunei. Chlorfortunone A inhibits transforming growth factor (TGF)-β activity .
    Chlorfortunone A
  • HY-160613

    EGFR Cancer
    EGFR/HER2-IN-11 (compound 20) is an orally active dual inhibitor for human epidermal growth factor receptor 2 (HER2) and epidermal growth factor receptor (EGFR), with IC50s of 7.7 and 22 nM, respectively. EGFR/HER2-IN-11 exhibits antitumor efficacy and inhibits proliferation against cancer cells BT-474 with GI50 of 601 nM .
    EGFR/HER2-IN-11
  • HY-N3482

    Others Neurological Disease
    Isogarciniaxanthone E (compound 1) is a natural product that can be found in Garcinia xanthochymus. Isogarciniaxanthone E enhances nerve growth factor-mediated neurite outgrowth .
    Isogarciniaxanthone E
  • HY-132259

    ABT-414

    Antibody-Drug Conjugates (ADCs) EGFR Cancer
    Depatuxizumab mafodotin is an antibody-drug conjugate (ADC) that specifically targets the epidermal growth factor receptor (EGFR). Depatuxizumab mafodotin can be used for cancer research .
    Depatuxizumab mafodotin
  • HY-B1016R

    PDGFR Cardiovascular Disease Cancer
    Trapidil (Standard) is the analytical standard of Trapidil. This product is intended for research and analytical applications. Trapidil is a vasodilator, an antiplatelet active molecule with specificity for platelet-derived growth factor.
    Trapidil (Standard)
  • HY-122347

    GW823296

    Neurokinin Receptor Neurological Disease
    Orvepitant (GW823296) is a compound with the ability to inhibit pruritus induced by cancer epidermal growth factor receptor inhibitor (EGFRI) and is a neurokinin-1 receptor antagonist.
    Orvepitant
  • HY-14754
    Salirasib
    5+ Cited Publications

    S-Farnesylthiosalicylic acid; Farnesyl Thiosalicylic Acid; FTS

    Ras Autophagy Cancer
    Salirasib is a Ras inhibitor that inhibits specifically both oncogenically activated Ras and growth factor receptor-mediated Ras activation, resulting in the inhibition of Ras-dependent tumor growth.
    Salirasib
  • HY-78349
    A 77-01
    1 Publications Verification

    TGF-β Receptor Cancer
    A 77-01 is a potent inhibitor of transforming growth factor (TGF)-β type I receptor superfamily activin-like kinase ALK5 with an IC50 of 25 nM .
    A 77-01
  • HY-12806

    EGFR Cancer
    AG1557 is a specific and ATP competitive inhibitor of epidermal growth factor receptor (EGFR) tyrosine kinase, has a pIC50 value of 8.194 .
    AG1557
  • HY-10408
    Ki20227
    5 Publications Verification

    c-Fms VEGFR c-Kit PDGFR Inflammation/Immunology
    Ki20227 is an orally active and highly selective c-Fms tyrosine kinase (CSF1R) inhibitor with IC50s of 2 nM, 12 nM, 451 and 217 nM for CSF1R, VEGFR2 (vascular endothelial growth factor receptor-2), c-Kit (stem cell factor receptor) and PDGFRβ (platelet-derived growth factor receptor β). Ki20227 suppresses osteoclast differentiation and osteolytic bone destruction .
    Ki20227
  • HY-147619

    FGFR Cancer
    FGFR-IN-4 is a potent inhibitor of FGFR. Fibroblast growth factor receptor (FGFR) is a tyrosine kinase receptor that binds to fibroblast growth factor ligands. FGFR-IN-4 has the potential for the research of cancer diseases (extracted from patent WO2022033532A1, compound 20) . FGFR-IN-4 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
    FGFR-IN-4
  • HY-147620

    FGFR Cancer
    FGFR-IN-5 is a potent inhibitor of FGFR. Fibroblast growth factor receptor (FGFR) is a tyrosine kinase receptor that binds to fibroblast growth factor ligands. FGFR-IN-5 has the potential for the research of cancer diseases (extracted from patent WO2022042612A1, compound 3) . FGFR-IN-5 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
    FGFR-IN-5
  • HY-111492
    DIM-C-pPhOCH3
    1 Publications Verification

    Nuclear Hormone Receptor 4A/NR4A Cancer
    DIM-C-pPhOCH3 is a Nur77 agonist. Nerve growth factor-induced Bα (NGFI-Bα, Nur77) is an orphan nuclear receptor.
    DIM-C-pPhOCH3

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: